ArticleMolecular & cellular proteomics : MCP2026
A Platform for High-throughput and Ultrasensitive Immunopeptidomics.
Article in Molecular & cellular proteomics : MCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mass spectrometry-based immunopeptidomics is a powerful approach for untargeted discovery of peptides presented on MHC molecules, which can guide the selection of vaccine antigens and immunotherapy targets. First-generation immunopeptidomics workflows require processing of hundreds of millions of cells using lengthy, manual procedures. More recent approaches focus on increasing either sensitivity or throughput, but rarely combine both aspects. Here, we describe a semiautomated immunopeptidomics platform that combines high sensitivity with high throughput by implementing highly optimized conditions for isolation of MHC class I and II peptides in a 96-well positive pressure device. Lysis in a small volume of 100 μl allows efficient MHC capture in a 96-well filter plate with optimal pore size for automated washing, elution, and C18 purification steps. Upon analysis of 25% of the eluate from 16 million cells, our workflow identified over 13,500 MHC I and 6000 MHC II peptides on a timsTOF single-cell proteomics mass spectrometer, operating in data-dependent acquisition-parallel accumulation-serial fragmentation mode. Exploring the sensitivity limits of our platform, we identified up to 1000 MHC I peptides, including hundreds of predicted binders, from as few as 20,000 JY cells. Validating the platform's performance for quantitative biological discovery, we report the identification of known and novel bacterial immunopeptides from U937 macrophages infected with Listeria monocytogenes or bacillus Calmette-Guérin. Together, our optimized immunopeptidomics platform enables robust immunopeptide detection from lower-input samples in a high-throughput fashion, enabling its use for biological applications where sample amounts are limiting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.